OTC Adverse Event Draft Guidance Addresses Multi-Product Reporting
This article was originally published in The Tan Sheet
Executive Summary
Over-the-counter drug companies need only submit one safety report when a serious adverse event involves multiple drugs, according to FDA's draft guidance on adverse event reporting and recordkeeping for nonprescription drugs
You may also be interested in...
Supplement AER Draft Guidance Omits Answers, But Recognizes Complexities
FDA's draft guidance for dietary supplement adverse event reports encourages firms to employ health care professionals to take information from consumers and other sources of adverse event calls
Adverse Event System Success Will Depend On Trained Reporters, Experts Say
Training potential reporters of adverse events may be crucial to the effectiveness of a mandatory adverse event reporting system, industry stakeholders say
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement